BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6189609)

  • 21. Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma.
    Uçkaya G; Ozet A; Arpaci A; Kömürcü S
    Nuklearmedizin; 1998; 37(8):297-8. PubMed ID: 9868713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncofetal antigens as tumor markers in the cytologic diagnosis of effusions.
    Orell SR; Dowling KD
    Acta Cytol; 1983; 27(6):625-9. PubMed ID: 6196931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography.
    Chung JK; Jang JJ; Lee DS; Lee MC; Koh CS
    J Nucl Med; 1994 Sep; 35(9):1499-505. PubMed ID: 8071700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
    Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
    Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tumor markers in bronchial cancer: do they have a role in daily practice?].
    Feintrenie X; Briancon S; Pichene M; Lamy P
    Rev Pneumol Clin; 1984; 40(6):345-54. PubMed ID: 6085181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pattern of ectopic hormone production in lung cancer.
    Bondy PK
    Yale J Biol Med; 1981; 54(3):181-5. PubMed ID: 6270916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological markers of human tumors and monitoring of cancer treatment.
    Tanneberger S; Nissen E; Ziegenbein R
    Arch Geschwulstforsch; 1979; 49(6):528-34. PubMed ID: 94534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections.
    Goldenberg DM; Sharkey RM; Primus FJ
    J Natl Cancer Inst; 1976 Jul; 57(1):11-22. PubMed ID: 794493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
    Wu Y; Wu Y; Wang L; Qu L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
    Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
    Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor markers: value and limitations in the management of cancer patients.
    Bates SE; Longo DL
    Cancer Treat Rev; 1985 Sep; 12(3):163-207. PubMed ID: 2416441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
    Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
    Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment.
    Waalkes TP; Abeloff MD; Woo KB; Ettinger DS; Ruddon RW; Aldenderfer P
    Cancer Res; 1980 Dec; 40(12):4420-7. PubMed ID: 6254646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The production of markers by bronchogenic carcinoma: a review.
    Primack A
    Semin Oncol; 1974 Sep; 1(3):235-44. PubMed ID: 4143486
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.